Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hoenicke, 2012, Immune surveillance of senescent cells: biological significance in cancer- and non-cancer pathologies, Carcinogenesis, 33, 1123, 10.1093/carcin/bgs124
Miska, 2012, Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self, Eur J Immunol, 42, 2584, 10.1002/eji.201242590
Klein, 2005, Surveillance against tumors: is it mainly immunological?, Immunol Lett, 100, 29, 10.1016/j.imlet.2005.06.024
Legha, 1996, Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha, Ann Oncol, 7, 827, 10.1093/oxfordjournals.annonc.a010762
Legha, 1998, Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma, J Clin Oncol, 16, 1752, 10.1200/JCO.1998.16.5.1752
O’Day, 2002, Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy, Clin Cancer Res, 8, 2775
Eton, 2002, Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial, J Clin Oncol, 20, 2045, 10.1200/JCO.2002.07.044
Bajetta, 2006, Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma, Ann Oncol, 17, 571, 10.1093/annonc/mdl007
Keilholz, 2005, Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group, J Clin Oncol, 23, 6747, 10.1200/JCO.2005.03.202
Ridolfi, 2002, Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial, J Clin Oncol, 20, 1600, 10.1200/JCO.20.6.1600
Zheng, 2013, Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome, Cancer Invest, 31, 197, 10.3109/07357907.2013.775294
Lafferty, 1980, An improved assay for interleukin 2 (lymphocyte growth factor) produced by mitogen-activated lymphocytes, Aust J Exp Biol Med Sci, 58, 533, 10.1038/icb.1980.55
Viganò, 2012, Positive and negative regulation of cellular immune responses in physiologic conditions and diseases, Clin Dev Immunol, 2012, 4857, 10.1155/2012/485781
Schwartz, 1990, Cell culture model for T lymphocyte clonal anergy, Science, 248, 1349, 10.1126/science.2113314
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239
Weiner, 2010, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nat Rev Immunol, 10, 317, 10.1038/nri2744
Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331
Lenschow, 1996, CD28/B7 system of T cell costimulation, Annu Rev Immunol, 14, 233, 10.1146/annurev.immunol.14.1.233
Schwartz, 1992, Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy, Cell, 71, 1065, 10.1016/S0092-8674(05)80055-8
Chen, 1992, Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4, Cell, 71, 1093, 10.1016/S0092-8674(05)80059-5
Townsend, 1993, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells, Science, 259, 368, 10.1126/science.7678351
Linsley, 1991, CTLA-4 is a second receptor for the B cell activation antigen B7, J Exp Med, 174, 561, 10.1084/jem.174.3.561
Tai, 2007, Induction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulation, Proc Natl Acad Sci U S A, 104, 13756, 10.1073/pnas.0706509104
Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8
Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int Immunol, 19, 813, 10.1093/intimm/dxm057
Long, 1999, Regulation of immune responses through inhibitory receptors, Annu Rev Immunol, 17, 875, 10.1146/annurev.immunol.17.1.875
Sidorenko, 2003, The dual-function CD150 receptor subfamily: the viral attraction, Nat Immunol, 4, 19, 10.1038/ni0103-19
Raimondi, 2006, Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation, J Immunol, 176, 4021, 10.4049/jimmunol.176.7.4021
Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027
Greenwald, 2005, The B7 family revisited, Annu Rev Immunol, 23, 515, 10.1146/annurev.immunol.23.021704.115611
Kinter, 2008, The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands, J Immunol, 181, 6738, 10.4049/jimmunol.181.10.6738
Latchman, 2004, PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells, Proc Natl Acad Sci U S A, 101, 10691, 10.1073/pnas.0307252101
Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6
Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330
Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat. Med., 5, 1365, 10.1038/70932
Tseng, 2001, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells, J Exp Med, 193, 839, 10.1084/jem.193.7.839
Matsumoto, 2004, B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism, J Immunol, 172, 2530, 10.4049/jimmunol.172.4.2530
Saresella, 2012, The PD-1/PD-L1 pathway in human pathology, Curr. Mol. Med., 12, 259, 10.2174/156652412799218903
Yu, 2004, Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice, Hepatology, 40, 1312, 10.1002/hep.20488
Dong, 2003, B7-H1 pathway and its role in the evasion of tumor immunity, J. Mol. Med., 81, 281, 10.1007/s00109-003-0430-2
Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm0902-1039c
Hino, 2010, Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, 116, 1757, 10.1002/cncr.24899
Hamanishi, 2007, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proc Natl Acad Sci U S A, 104, 3360, 10.1073/pnas.0611533104
Konishi, 2004, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, 10, 5094, 10.1158/1078-0432.CCR-04-0428
Thompson, 2004, Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target, Proc Natl Acad Sci U S A, 101, 17174, 10.1073/pnas.0406351101
Nakanishi, 2007, Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers, Cancer Immunol Immunother, 56, 1173, 10.1007/s00262-006-0266-z
Strome, 2003, B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma, Cancer Res, 63, 6501
Lyford-Pike, 2013, Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma, Cancer Res, 73, 1733, 10.1158/0008-5472.CAN-12-2384
Ohigashi, 2005, Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin Cancer Res, 11, 2947, 10.1158/1078-0432.CCR-04-1469
Karim, 2009, Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma, Clin Cancer Res, 15, 6341, 10.1158/1078-0432.CCR-09-1652
Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733
Nomi, 2007, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, 13, 2151, 10.1158/1078-0432.CCR-06-2746
Wu, 2006, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem, 108, 19, 10.1016/j.acthis.2006.01.003
Routh, 2008, B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence, J Urol, 179, 1954, 10.1016/j.juro.2008.01.056
Wintterle, 2003, Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis, Cancer Res, 63, 7462
Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3
Cho, 2011, Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma, Oral Oncol, 47, 1148, 10.1016/j.oraloncology.2011.08.007
Khalili, 2012, Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma, Clin Cancer Res, 18, 5329, 10.1158/1078-0432.CCR-12-1632
Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792
Gadiot, 2011, Overall survival and PD-L1 expression in metastasized malignant melanoma, Cancer, 117, 2192, 10.1002/cncr.25747
Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127, 10.1126/scitranslmed.3003689
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690
Hodi, 2012, Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL)
Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133
Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694
Mkrtichyan, 2012, B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets, J Immunol, 189, 2338, 10.4049/jimmunol.1103085
Slingluff, 2011, The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?, Cancer J, 17, 343, 10.1097/PPO.0b013e318233e5b2
Rosenblatt, 2011, PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine, J Immunother, 34, 409, 10.1097/CJI.0b013e31821ca6ce
Pilon-Thomas, 2010, Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma, J Immunol, 184, 3442, 10.4049/jimmunol.0904114
Li, 2007, Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1, J Clin Immunol, 27, 117, 10.1007/s10875-006-9053-z
Palazón, 2011, Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes, Cancer Res, 71, 801, 10.1158/0008-5472.CAN-10-1733
Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107
Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369
Thompson, 2006, Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up, Cancer Res, 66, 3381, 10.1158/0008-5472.CAN-05-4303
Mu, 2011, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, 28, 682, 10.1007/s12032-010-9515-2
Gao, 2009, Overexpression of PD-L1 Significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma, Clin Cancer Res, 15, 971, 10.1158/1078-0432.CCR-08-1608
Cariani, 2012, Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma, PLoS ONE, 7, e32493, 10.1371/journal.pone.0032493
Zeng, 2011, Upregulation of circulating PD-L1/PD 1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma, PLoS ONE, 6, e23621, 10.1371/journal.pone.0023621
Hsu, 2010, Increase of programmed death-1 expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma, Mod Pathol, 23, 1393, 10.1038/modpathol.2010.130
Droeser, 2013, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, 10.1016/j.ejca.2013.02.015
Wahlin, 2010, A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 positive, regulatory, cytotoxic, and helper T cells and macrophages, Clin Cancer Res, 16, 637, 10.1158/1078-0432.CCR-09-2487
Takahashi, 2013, Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era, Eur J Haematol, 90, 286, 10.1111/ejh.12075
Richendollar, 2011, Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Hum Pathol, 42, 552, 10.1016/j.humpath.2010.08.015
Muenst, 2009, Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival, Hum Pathol, 40, 1715, 10.1016/j.humpath.2009.03.025
Shi, 2011, PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients, Int J Cancer, 128, 887, 10.1002/ijc.25397
Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609
Berger, 2008, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies, Clin Cancer Res, 14, 3044, 10.1158/1078-0432.CCR-07-4079
McDermott, 2012, Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC)
Patnaik, 2012, Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
Kudchadkar, 2012, Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma
Brahmer, 2012, Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC)
Tykodi, 2012, PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors